ALA-105 / Arovella Therap, SparX - LARVOL DELTA

Allogeneic CAR-iNKT cell therapy targeting CLDN18.2-positive gastric and pancreatic cancers (AACR 2026) - "CLDN18.2 CAR-iNKT cells exhibited potent and sustained cytotoxic activity against CLDN18.2-positive tumor cells, and co-expression of IL-12-TM improved the persistence and durability of response under repeated high tumour burden. These findings support the potential of cytokine-armoured CLDN18.2-directed CAR-iNKT cells as an allogeneic cell therapy for the treatment of gastric and pancreatic cancers."

IO biomarker • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18 • IL12A • NKG2D

A Whole-Cell Catalytic System for Equol Production Based on Daidzein Reductase Engineering. (PubMed, Molecules) - "Upon increasing the daidzein concentration to 2 mM, the reaction reached equilibrium within 5 h, producing 384.6 mg/L (S)-equol, which highlights the mutant's excellent potential for high-substrate-concentration applications. This study not only provides novel mechanistic insights into DZNR catalysis but also successfully establishes a DZNR variant with enhanced activity, offering an efficient biocatalytic component for the industrial-scale biomanufacturing of (S)-equol and thereby advancing the development of green biosynthesis technologies for this valuable compound."

Journal

Arovella Therapeutics Ltd…is pleased to announce that it has further confirmed the functionality of its novel claudin 18.2 (CLDN18.2)-targeting chimeric antigen receptor (CAR) by demonstrating that CLDN18.2 CAR-T cells robustly eliminate pancreatic cancer cells that express CLDN18.2. (Arovella Therap Press Release) - "The results demonstrated that CAR-T cells expressing Arovella’s CLDN18.2 CAR displayed robust killing of pancreatic cancer cells, and the activity was similar to that observed for a control CAR generated based upon the CARsgen Therapeutics CT041 CAR."

Preclinical • Pancreatic Cancer

AROVELLA FULLY FUNDED TO COMPLETE PHASE 1 WITH $20M PLACEMENT (Arovella Therap Press Release) - "Arovella Therapeutics...pleased to announce that it has received firm commitments from institutional and sophisticated investors, to raise approximately $20 million (before costs) under a placement of 117.6 million new fully paid....Funds raised under the Placement will be used to complete and report data from the planned phase 1, first-in-human clinical trial for Arovella’s lead product, ALA-101. The phase 1 clinical trial is for patients with CD19- positive non-Hodgkin’s lymphoma and leukemia. Funds raised under the placement will also be used to strengthen Arovella’s iNKT cell therapy pipeline and advance Arovella’s solid tumour products, and for general working capital purposes."

Financing • Gastric Cancer • Leukemia • Non-Hodgkin’s Lymphoma • Pancreatic Cancer

AROVELLA FULLY FUNDED TO COMPLETE PHASE 1 WITH $20M PLACEMENT (Arovella Therap Press Release) - "Over the remainder of CY2025, Arovella expects to achieve several critical milestones, including: Securing IND approval through the US FDA to conduct a phase 1 clinical trial in CD19-positive non-Hodgkin’s lymphoma and leukemia; Commencing a phase 1 clinical trial; Obtaining clinical data from initial patients dosed with ALA-101; and Securing proof-of-concept data for its solid tumour programs directed toward gastric and/or pancreatic cancer."

IND • New P1 trial • Preclinical • Gastric Cancer • Leukemia • Non-Hodgkin’s Lymphoma • Pancreatic Cancer

Arovella Therapeutics' cell therapies potential highlighted in Spark Plus note (Proactiveinvestors) - "A new desk note from Spark Plus analyst Cyprus Sia has provided a comprehensive look at Arovella Therapeutics Ltd (ASX:ALA) and the work the biotech company is doing towards developing invariant natural killer T (iNKT) cell therapies, including its pioneering ‘armoured’ CAR-iNKT product...The company intends to commence a Phase 1 clinical trial for CD19+ lymphoma and leukaemia patients in late 2024....By the end of 2024, ALA will attempt to produce CLDN18.2- iNKT cells, integrate IL-12-TM into its solid tumour programs, and validate their activities in preclinical studies."

New P1 trial • Preclinical • Gastric Cancer • Gastrointestinal Cancer • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Pancreatic Cancer • Solid Tumor

Arovella Therapeutics to fully focus on lead cancer programs on terminating DKK1 licence (Investing.com) - "Following a strategic review of its pipeline, Arovella Therapeutics Ltd...has terminated its licence agreement with MD Anderson Cancer Centre for the DKK1-targeting technology as it concentrates on its invariant Natural Killer T (iNKT) cell therapy platform. This decision enables the company to focus resources on its lead program, ALA-101 for CD19+ blood cancers, and the newly licensed ALA-105 for Claudin 18.2+ solid tumours, as well as its ongoing collaboration with Imugene Ltd, combining ALA-101 with Imugene’s onCARlytics platform, and the potential acquisition of a cytokine technology from the Lineberger Comprehensive Cancer Center."

Licensing / partnership • Hematological Malignancies • Oncology • Solid Tumor